

March 15, 2024

**Launch of “GOBIK Aqueous Suspension Syringes”,
Pertussis, Diphtheria, Tetanus, Inactivated Polio
and Hib Combined Vaccine**

The Research Foundation for Microbial Diseases of Osaka University (Headquarters: Suita-city, Osaka; Director General: Yoshihiro Yoneda; hereafter, "BIKEN"), Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director: Akihiro Tsujimura; hereafter, "MTPC") and Pfizer Japan Inc. (Head Office: Shibuya-ku, Tokyo; President: Akihisa Harada; hereafter, "Pfizer") announced that "GOBIK Aqueous Suspension Syringes" (hereafter "GOBIK"), Adsorbed Diphtheria-Purified Pertussis-Tetanus-Inactivated Polio-Haemophilus type b conjugate Combined Vaccine, was launched in Japan today.

GOBIK is a vaccine that combined the antigenic components of TETRABIK (adsorbed diphtheria-purified pertussis-tetanus-inactivated polio [Sabin strain] combined vaccine) with those of Haemophilus influenzae type b (Hib) . It is expected that the use of GOBIK will reduce the number of shots of routine vaccinations and the burden on infants and guardians.

GOBIK is a vaccine jointly developed by BIKEN and MTPC, and was first approved in Japan as the combination vaccine for five diseases on March 27, 2023. GOBIK is manufactured by BIKEN, which has a marketing authorization, distributed by MTPC and jointly promoted by MTPC and Pfizer.

Routine vaccinations with GOBIK will begin on April 1 this year. BIKEN, MTPC and Pfizer will continue to contribute to public health in Japan through the manufacture, stable supply and promotion of GOBIK.

◆ **Contact information**

Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Group,
Corporate Communications Div., Osaka Corporate Communications Dept.)
+81-6-6205-5119

Public Relations Section, The Research Foundation for Microbial Diseases of
Osaka University +81-6-6877-4802

◆ **About Research Foundation for Microbial Diseases of Osaka University**

The BIKEN Foundation is engaged in the research, development, and supply of vaccines and provides advanced laboratory test services. As a pioneer of university ventures, the BIKEN Foundation has contributed to public health since its establishment in 1934 based on its mission “Protect the precious lives of people around the world through excellent vaccines.” Toward a healthy society, the BIKEN Foundation will continue to pursue achievements with its proprietary research and development expertise and biotechnologies to meet society’s expectations.

<https://www.biken.or.jp/english>

◆ **About Mitsubishi Tanabe Pharma Corporation**

Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquartered in Dosho-machi, Osaka, the birthplace of Japan’s pharmaceutical industry. MCG has positioned health care as its strategic focus in its management policy, “Forging the future”. MTPC sets the MISSION of “Creating hope for all facing illness”. To that end, MTPC is working on the disease areas of central nervous system, immuno-inflammation, diabetes and kidney, and cancer. MTPC is focusing on “precision medicine” to provide drugs with high treatment satisfaction by identifying patient populations with high potential for efficacy and safety. In addition, MTPC is working to develop “around the pill solutions” to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis. For more information, go to <https://www.mt-pharma.co.jp/e/>

◆ **About Pfizer**

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for

quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 175 years, Pfizer has worked to make a difference for all who rely on us. For more information, go to www.pfizer.com (Pfizer Inc.), www.pfizer.co.jp, [Instagram](#), [X](#) (Pfizer Japan Inc.)